Synaptogenix Inc (SNPX)

[SF Wolf]

The excerpts below from today’s Bloomberg article mirrors what Dr. Alkon of NTRP said in his BIO CEO presentation yesterday. Essentially, treating amyloid deposits is treating one of the symptoms of AD not the underlying cause and will not be successful.

Merck Stops Alzheimer's Study After `No Chance’ of Benefit

“It’s very disappointing, once again,” said David Knopman, a professor of neurology at the Mayo Clinic in Rochester, Minnesota…
Merck’s drug and others target a plaque, called amyloid, thought to be a cause of the disease. While more such treatments are in development from companies including Biogen Inc. and Roche Holding AG, many researchers now believe that administering drugs after amyloid has built up in the brain may be too late.

“There is mounting evidence -- of which this is another piece -- that removing amyloid once people have established dementia is closing the barn door after the cows have left,” Knopman said.

https://www.bloomberg.com/news/articles/2017-02-14/merck-stops-alzheimer-s-study-after-no-chance-of-effectiveness